Pennsylvania 2025-2026 Regular Session

Pennsylvania House Bill HB704 Latest Draft

Bill / Introduced Version

                             
PRINTER'S NO. 1437 
THE GENERAL ASSEMBLY OF PENNSYLVANIA
HOUSE BILL 
No.704 
Session of 
2025 
INTRODUCED BY MULLINS, CUTLER, SCHLOSSBERG, NEILSON, McNEILL, 
KHAN, FLICK, JAMES, GIRAL, SANCHEZ, PIELLI, HANBIDGE, HILL-
EVANS, CIRESI, MENTZER, HOWARD, DONAHUE, BRENNAN, McANDREW, 
FREEMAN, PICKETT, DELLOSO, TWARDZIK, O'MARA, FLEMING, DEASY, 
CERRATO, GREEN, GILLEN, POWELL, WAXMAN, PROKOPIAK, T. DAVIS, 
PASHINSKI, WEBSTER, STEELE, CEPEDA-FREYTIZ, MAYES, MALAGARI, 
SHUSTERMAN, BOROWSKI, OLSOMMER, INGLIS, KENYATTA, BURGOS, 
GAYDOS, SCHMITT, STAATS, MERSKI, DOUGHERTY AND WARREN, 
APRIL 22, 2025 
REFERRED TO COMMITTEE ON HEALTH, APRIL 22, 2025 
AN ACT
Establishing the Neurodegenerative Disease Research Program and 
the Neurodegenerative Disease Research Program Fund; and 
imposing duties on the Department of Health.
The General Assembly of the Commonwealth of Pennsylvania 
hereby enacts as follows:
Section 1.  Short title.
This act shall be known and may be cited as the 
Neurodegenerative Disease Research Program Act.
Section 2.  Definitions.
The following words and phrases when used in this act shall 
have the meanings given to them in this section unless the 
context clearly indicates otherwise:
"Biorepository."  An entity that receives, stores, processes 
or disseminates biospecimens, the derivatives of biospecimens or 
relevant data regarding biospecimens.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15 "Department."  The Department of Health of the Commonwealth.
"Eligible applicant."  An institution engaged in 
neurodegenerative disease research.
"Fund."  The Neurodegenerative Disease Research Program Fund 
established under section 5(a).
"Institution."  Any of the following located in this 
Commonwealth:
(1)  An academic clinical research entity that conducts 
neurodegenerative disease research.
(2)  An institution of higher education that conducts 
neurodegenerative disease research.
"Neurodegenerative disease."  Conditions characterized by the 
progressive loss of nerve cells in the brain or spinal cord, 
leading to functional decline and often resulting in 
debilitating conditions such as dementia or movement disorders, 
including, but not limited to, amyotrophic lateral sclerosis, 
Alzheimer's disease, Huntington's disease or Parkinson's 
disease.
"Neurodegenerative disease research."  Health research on 
neurodegenerative diseases. The term includes:
(1)  Biomedical research.
(2)  Clinical research.
(3)  Health services research.
(4)  Research regarding the establishment of a Statewide 
biorepository.
(5)  Research regarding a Statewide tissue bank.
"Program."  The Neurodegenerative Disease Research Program 
established under section 3(a).
"Tissue bank."  An entity that is licensed, accredited or 
regulated under Federal or State law to engage in the recovery, 
20250HB0704PN1437 	- 2 - 
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30 screening, testing, processing, storage or distribution of 
tissue.
Section 3.  Neurodegenerative Disease Research Program.
(a)  Establishment.--The Neurodegenerative Disease Research 
Program is established within the department.
(b)  Purpose.--The program shall provide grants to eligible 
applicants to fund neurodegenerative disease research projects 
on neurodegenerative disease and related infrastructure.
(c)  Administration.--The department shall implement and 
administer the program in accordance with this act.
(d)  Application form.--
(1)  The department shall develop an application form 
which must be completed and approved before an eligible 
applicant can receive a grant under the program.
(2)  The application form under this subsection must 
include:
(i)  Eligibility criteria to receive a grant under 
the program.
(ii)  Deadlines for submittal of a completed 
application form.
(iii)  Information to be submitted with a completed 
application, including:
(A)  Contact information.
(B)  Proof of eligibility for a grant under the 
program.
(C)  The purpose and amount of the requested 
grant under the program.
(iv)  Certification that the proposed research has 
undergone appropriate Institutional Review Board review 
and peer review as necessary.
20250HB0704PN1437 	- 3 - 
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30 (3)  The department shall post the application form under 
this subsection on its publicly accessible Internet website.
(e)  Determination.--The department shall develop a process 
for:
(1)  The submittal and review of a completed application 
form for grants under the program, including a timeline for 
making a determination on the application and notice of the 
award of grants under the program.
(2)  The disbursement of grants under the program to 
eligible applicants, including any limit on the amount of a 
grant disbursed to an eligible applicant.
(3)  The general administration of the program, including 
the maintenance of records regarding the program.
(f)  Reports.--Within 90 days after the grant period ends, 
each recipient shall submit a report to the department which 
shall include:
(1)  The progress made in achieving expected research 
goals and objectives.
(2)  Any major discoveries, new drugs and new approaches 
for prevention, diagnosis and treatment which are 
attributable to the completed research project.
(3)  Any other information deemed necessary by the 
department.
Section 4.  Funding formula.
(a)  Eligibility.--If an institution has received funding for 
neurodegenerative disease research from the National Institutes 
of Health during any of the four preceding Federal fiscal years 
in which money for that research was disbursed, the institution 
shall be eligible to receive a grant under the program.
(b)  Fund distribution.--Money to be distributed to each 
20250HB0704PN1437 	- 4 - 
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30 eligible applicant shall be calculated by dividing the total 
number of eligible applicants by the total amount appropriated 
in a fiscal year.
Section 5.  Neurodegenerative Disease Research Program Fund.
(a)  Establishment.--The Neurodegenerative Disease Research 
Program Fund is established in the State Treasury to carry out 
the purposes of the program.
(b)  Operation.--All money deposited into the fund and 
interest and other earnings on the money in the fund are 
appropriated to the department on a continuing basis to award 
grants under the program.
(c)  Fund sources.--The department may solicit and accept 
funding for the program, including money appropriated by the 
General Assembly, Federal money, grants, donations, gifts and 
other payments from any source, which shall be deposited into 
the fund.
Section 6.  Accountability.
An eligible institution that receives a grant under the 
program shall be subject to a performance review by the 
department upon completion of a neurodegenerative disease 
research project or more often as deemed necessary by the 
department. The performance review shall be based on an 
evaluation process by the department.
Section 7.  Reports.
(a)  Annual reports required.--No later than September 1, 
2025, and each September 1 thereafter, the department shall 
issue an annual report detailing the operation of the program 
and fund during the preceding year.
(b)  Contents.--Each annual report under this section must 
include the following:
20250HB0704PN1437 	- 5 - 
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30 (1)  The number of eligible applicants that sought a 
grant under the program.
(2)  The amount of the grant that each eligible applicant 
received under the program.
(3)  The number of applicants that were denied, in whole 
or in part, a grant under the program, including the reasons 
for the full or partial denial.
(4)  The money remaining in the fund.
(5)  Any other information deemed necessary by the 
department.
(c)  Transmittal.--Each annual report under this section 
shall be transmitted to the following:
(1)  The Governor.
(2)  The President pro tempore of the Senate.
(3)  The Speaker of the House of Representatives.
(4)  The Minority Leader of the Senate.
(5)  The Minority Leader of the House of Representatives.
(6)  The chairperson and minority chairperson of the 
Appropriations Committee of the Senate.
(7)  The chairperson and minority chairperson of the 
Appropriations Committee of the House of Representatives.
(d)  Posting.--The department shall post each annual report 
under this section on the publicly accessible Internet website 
of the department.
Section 8.  Rules and regulations.
The department shall adopt or promulgate rules or regulations 
necessary to implement and administer this act.
Section 9.  Effective date.
This act shall take effect immediately.
20250HB0704PN1437 	- 6 - 
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29